Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Law & Politics

17 Jan 2022

KGK Science Response to Health Canada’s announced changes to the Special Access Program (SAP)

Clinical trials are key to gathering the data needed to bring the government for changing the narrative on psychedelics....

By Microdose

Psychedelic Groundbreakers

13 Jan 2022

Psychedelic Groundbreakers: Entheo Ventures

This week's Psychedelic Groundbreaker is Entheo Ventures....

By Microdose

Industry

13 Jan 2022

PharmaTher Receives FDA Approval for Ketamine Phase 2 Trial

PharmaTher has taken another important step in its clinical trial process....

By Microdose

Breaking News

11 Jan 2022

Awakn Announces Positive Results from Phase II Trial of Alcohol Use Disorder

Primary and Secondary Endpoints Achieved, Including 86% Abstinence Over 6 Months Post Treatment and No Serious Adverse Events...

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Events

6 Jan 2022

PsyCap Recap: Zeifmans

Rounding out the coverage from Microdose's last Psychedelic Capital event, a roundtable discussion with some of the industry’s top minds, giving insights into a variety of topics....

By Microdose

Industry

6 Jan 2022

Field Trip to Apply on Behalf of Patients for Psychedelic Access Program

Following up on yesterday's news that the Canadian government has officially amended regulations on its Special Access Program, Field Trip has announced that will help patients navigate these bureaucratic waters....

By Microdose

Press Releases

6 Jan 2022

MHRA Guidance for Regulatory Decision-Making Supports Albert Labs’ Licensing Pathway

MHRA Guidance on the use of Real-World Data in Clinical Studies for Regulatory Decision-Making Supports Albert Labs' Licensing Pathway NEWS PROVIDED BY Albert Labs Inc....

By Microdose

Industry

3 Jan 2022

Heath Canada Amends Special Access Program

The SAP is a process by which healthcare practitioners can petition the government for special access to restricted drugs on behalf of their patients....

By Microdose

Events

27 Dec 2021

PsyCap Recap: KGK Science Helps Navigate Psychedelic Product Development

KGK Science is a full-service contract research organization (CRO) supporting the nutraceutical, cannabis and psychedelic industries....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.